Silence Therapeutics Plc American Depository Share - SLN STOCK NEWS

Silence Therapeutics and Mallinckrodt have commenced work on a third research target as part of their RNAi collaboration for complement-mediated diseases. Silence will receive a $2 million milestone payment, contributing to a potential total of $2 billion in milestone payments across three targets. Additionally, Silence stands to gain tiered double-digit royalties on net sales for each candidate developed. This collaboration is aimed at leveraging Silence’s mRNAi GOLD™ platform to develop therapeutics that inhibit the complement cascade, addressing significant medical needs.

Silence Therapeutics will participate in two virtual investor conferences in March 2021 to provide important business updates. The Cowen 41st Annual Health Care Conference is scheduled for March 1 at 10:20 AM EST, while the H.C. Wainwright Global Life Sciences Conference will be available on-demand on March 9. Interested investors can access live webcasts and archived replays through the company's website. Silence Therapeutics specializes in developing siRNA therapeutics for significant unmet medical needs, with key products including SLN360 and SLN124.

Silence Therapeutics, AIM: SLN and Nasdaq: SLN, will present at the 2021 SVB Leerink Global Healthcare Conference on February 26th at 9:20 a.m. EST. CEO Mark Rothera will provide a company update, focusing on their innovative siRNA therapeutics aimed at significant unmet medical needs. A live webcast will be available on Silence's website, with a replay following the event. The company's proprietary platform is pivotal for developing medicines targeting disease-associated genes, including product candidates SLN360 and SLN124.

Silence Therapeutics has commenced dosing in the Phase I clinical trial of SLN360, targeting cardiovascular disease linked to elevated lipoprotein(a) levels. The APOLLO trial aims to assess the safety, tolerability, and pharmacokinetics of SLN360 in approximately 88 participants with Lp(a) levels ≥60 mg/dL. Results from the initial dosing phase are expected later this year. SLN360, a gene silencing therapy, seeks to lower elevated Lp(a) and reduce associated heart disease risks.

Silence Therapeutics plc announced an oversubscribed private placement of 2,022,218 American Depositary Shares (ADSs) at $22.50 per share, raising approximately $45 million. The funds will primarily support the development of Silence's messenger RNAi GOLD™ platform and general corporate purposes. The placement is expected to close on February 9, 2021, with new shares representing 6.8% of the company's issued share capital. The firm plans to register the ADSs with the SEC for resale. Notably, Silence anticipates releasing clinical data from its mRNAi GOLD™ platform in the first half of 2021.

Silence Therapeutics has appointed Michael H. Davidson, MD, a lipidology expert, to its Board of Directors to bolster its development of SLN360, aimed at treating cardiovascular diseases. Dr. Davidson brings over 30 years of experience in clinical trials and has a notable history of founding and leading successful biotech companies, enhancing the expertise within Silence's pipeline. This strategic addition is expected to provide valuable insights as Silence advances its GalNAc siRNA platform and prepares for clinical progress with SLN360.

Silence Therapeutics has appointed Craig Tooman as its new Chief Financial Officer effective immediately. Tooman brings over 30 years of biopharmaceutical experience, including roles as CFO at Vyome Therapeutics and Aratana Therapeutics. His expertise in financial strategies and business development is expected to strengthen Silence's position in the RNAi market, especially as the company advances clinical candidates SLN360 and SLN124. CEO Mark Rothera emphasized the strategic timing of this appointment amid significant growth opportunities for the firm.

Silence Therapeutics (AIM: SLN, Nasdaq: SLN) announced its participation in two upcoming virtual U.S. investor conferences. The presentations will include a fireside chat at the H.C. Wainwright BioConnect 2021 Conference on January 11, 2021, at 6:00 a.m. EST, and at the ICR Conference 2021 on January 14, 2021, from 8:30-9:10 a.m. EST. Live webcasts can be accessed on the company's website, with archived replays available for 60 days post-event.

Silence is focused on siRNA therapeutics for significant unmet medical needs.

Silence Therapeutics presented positive pre-clinical data for SLN360 at the American Heart Association's 2020 conference. The data reveals no adverse effects, demonstrating safe biodistribution primarily in the liver and kidneys. SLN360 targets elevated lipoprotein(a), a genetic risk factor for cardiovascular diseases, and is set to enter in-human testing following promising results. The ongoing Phase I APOLLO trial aims to assess safety and efficacy in patients with elevated Lp(a) levels, potentially offering a novel treatment for this unmet medical need.